Ignite Creation Date:
2024-05-05 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00263705
Status:
COMPLETED
Last Update Posted:
2011-02-24
First Post:
2005-09-13
Brief Title:
Adjuvant Capecitabine in Elderly Patients With Breast Cancer a Phase II Study
Sponsor:
Jules Bordet Institute
Organization:
Jules Bordet Institute
Study Overview
Official Title:
Adjuvant Capecitabine in Elderly Patients With Breast Cancer a Phase II Study
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Determination of guidelines regarding the use of adjuvant chemotherapy for early breast cancer in this population of Patients over 70 years old
Detailed Description:
Patients over 70 years old are under represented in clinical trials and there are no clear guidelines regarding the use of adjuvant chemotherapy for early breast cancer in this population Whether CT retains the benefit conferred to younger patients remains uncertain Moreover there is extensive data regarding the increasing incidence and severity of side effects such as myelotoxicity mucositis and cardiotoxicity with CT in this population The efficacy and safety of CT in aged patients have been evaluated in different studies most of them in haematological malignancy Clearly the patients functional declines with age and the risk for CT toxicity rises with age There is no standard of care regarding adjuvant chemotherapy for breast cancer in patients older than 70 years old
This is a pilot study evaluating the feasibility and safety of 6 cycles of capecitabine in patients aged 70 years or more with high-risk early invasive breast cancer who have undergone optimal surgery
The primary end point is to evaluate the possibility of delivering 6 cycles of capecitabine at the dose of 1000 mgm² BID days 1 to 14 every 3 weeks in terms of rate of patients who will receive an acceptable relative dose intensity RDI
Secondary end points are safety including the evaluation of possible impact of treatment on the functional cognitive and emotional status of the patient and evaluating if some form of geriatric assessment add any information to the classic inclusion criteria screening in terms of prediction of treatment compliance and toxicity
The study is being conducted at the Jules Bordet Institute The planned accrual is 43 patients
This is a pilot study evaluating the feasibility and safety of 6 cycles of capecitabine in patients aged 70 years or more with high-risk early invasive breast cancer who have undergone optimal surgery
The primary end point is to evaluate the possibility of delivering 6 cycles of capecitabine at the dose of 1000 mgm² BID days 1 to 14 every 3 weeks in terms of rate of patients who will receive an acceptable relative dose intensity RDI
Secondary end points are safety including the evaluation of possible impact of treatment on the functional cognitive and emotional status of the patient and evaluating if some form of geriatric assessment add any information to the classic inclusion criteria screening in terms of prediction of treatment compliance and toxicity
The study is being conducted at the Jules Bordet Institute The planned accrual is 43 patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None